BIAF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, bioAffinity Technologies Inc (BIAF) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks clear positive trading signals, has mixed technical indicators, and faces challenges in financial performance. While the company's CyPath® Lung test shows promise as a product, the financials and lack of significant trading trends or analyst ratings suggest a wait-and-see approach is more prudent.
The MACD histogram is positive but contracting, indicating weakening momentum. RSI is neutral at 47.105, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key support is at 0.936, and resistance is at 1.31, with the current price of 1.09 sitting near the pivot point of 1.123. Overall, the technical indicators do not suggest a strong buy signal.
The company's CyPath® Lung test demonstrates high sensitivity (92%) and specificity (87%) for detecting lung cancer in small nodules, which could reduce the need for invasive biopsies. This represents a significant advancement in noninvasive cancer diagnostics and could drive future growth if successfully commercialized.
The company's financial performance in 2025/Q3 is weak, with revenue dropping by 38.48% YoY, EPS declining by 2.07% YoY, and gross margin falling by 16.38% YoY. Additionally, there are no significant trading trends among hedge funds or insiders, and no recent congress trading data is available. The lack of analyst ratings or price target changes also limits visibility into market sentiment.
In 2025/Q3, the company reported a revenue drop of 38.48% YoY to $1,446,066. Net income improved by 152.45% YoY but remains negative at -$5,051,084. EPS declined by 2.07% YoY to -4.74, and gross margin fell by 16.38% YoY to 27%. Overall, the financial performance indicates significant challenges, with declining revenue and profitability metrics.
No data available for analyst ratings or price target changes.
